Linezolid (Synonyms: PNU-100766)

Name: Linezolid
Brand: MedChemExpress
SKU: HY-10394
Rating: 5.0 (52 reviews)

Cat. No.: HY-10394 Purity: 99.94%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics.

For research use only. We do not sell to patients.

CAS No. : 165800-03-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 52 publication(s) in Google Scholar

Other Forms of Linezolid:

52 Publications Citing Use of MCE Linezolid

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

Bio/Physico-chemical Assay

: Linezolid purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]; Dose-response curves for Linezolid (LZD: 0.0625-256 μg/mL) against M. abscessus ∆eis2 or M. abscessus Eis2 T258R strains complemented with pOLYG-aac(3)IV-eis2 overexpression or pOLYG-aac(3)IV control vector.

: Linezolid purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]; Efficacy of CLR, Linezolid (LZD: 100 mg/kg) and FF-NH2 versus saline vehicle in an acute mouse infection model. GM-CSF KO mice were infected with M. abscessus WT, treatment began on day 2 and continued for 9 days (CLR/LZD oral daily, FF-NH2 subcutaneous twice daily). Bacterial burden (colony forming units (c.f.u.)) was measured in lung, liver and spleen at day 12 post-infection.

: Linezolid purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]; MH-S cells were pretreated with insulin, linezolid, or combination of insulin (50 nmol/L) and Linezolid (0.25 μg/ml) for 1 h, next these cells were treated with high glucose (30 mmol/L) and/or S. aureus 8325–4, high glucose and/or S. aureus DU1090 for 4 h, then the cell viability was tested by CCK8 kit;

: Linezolid purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]; MH-S cells were pretreated with insulin, linezolid, or a combination of insulin (50 nmol/L) and linezolid (0.25 μg/ml) for 1 hour, and then treated with high glucose (30 mmol/L) and/or Staphylococcus aureus 8325-4, or high glucose and/or Staphylococcus aureus DU1090 for 4 hours. The glucose content in the MH-S cell culture medium was detected using a glucose content detection kit.

: Linezolid purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]; MH-S cells were pretreated with insulin, linezolid and combination of insulin (50 nmol/L) and Linezolid (0.25 μg/ml) for 1 h, next these cells were treated with high glucose (30 mmol/L) and/or S. aureus 8325–4 (1 × 107 CFUs), high glucose and/or S. aureus DU1090 (1 × 107 CFUs) for 4 h. Then the expressions of TLR2, MAPKs (JNK, ERK, p38, p-JNK, p-ERK1/2, and p-p38), NLRP3 inflammasome proteins (NLRP3, ASC, Caspase-1, IL-1β, IL-18) and MIP-2 were detected by each pathway inhibitor treatment was used to further explore the upstream and downstream relationships among TLR2, MAPKs and NLRP3-related inflammatory pathways in MH-S cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Oxazolidinone

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	105.4 μM Compound: linezolid	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
H9c2	IC₅₀	16.9 μg/mL Compound: Linezolid	Cytotoxicity against rat H9c2 cells incubated for 24 hrs by MTT assay Cytotoxicity against rat H9c2 cells incubated for 24 hrs by MTT assay	[PMID: 38505856]
H9c2	IC₅₀	7.98 μM Compound: Linezolid	Inhibition of mitochondrial protein synthesis in rat H9c2 cells measured after 5 days by ELISA Inhibition of mitochondrial protein synthesis in rat H9c2 cells measured after 5 days by ELISA	[PMID: 32666789]
H9c2	IC₅₀	8.71 μM Compound: Linezolid	Inhibition of mitochondrial protein synthesis in rat H9c2 cells after 5 days by In-Cell ELISA Inhibition of mitochondrial protein synthesis in rat H9c2 cells after 5 days by In-Cell ELISA	[PMID: 28523106]
HEK293-A	IC₅₀	215 μg/mL Compound: 1; LZN	Cytotoxicity against HEK293A cells after 48 hrs by MTT assay Cytotoxicity against HEK293A cells after 48 hrs by MTT assay	10.1039/C5MD00101C
HeLa	IC₅₀	> 100 μg/mL Compound: Linezolid	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 17456595]
HeLa	IC₅₀	> 400 μg/mL Compound: Linezolid	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HepG2	EC₅₀	> 30 μM Compound: Linezolid	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by CellTiter-Glo assay	[PMID: 31383589]
HepG2	IC₅₀	> 25 μM Compound: 1	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30553735]
HepG2	IC₅₀	> 25 μM Compound: 1; Zyvox	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30218910]
HepG2	IC₅₀	> 25 μM Compound: Linezolid	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31654879]
HepG2	IC₅₀	> 30 μM Compound: Linezolid	Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 38761790]
HepG2	IC₅₀	> 64 μM Compound: Linezolid	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability Cytotoxicity against human HepG2 cells assessed as reduction in cell viability	[PMID: 31676225]
Hepatocyte	IC₅₀	17 μM Compound: 1 (Linezolid)	Compound was evaluated for inhibition of Mono aminoxidase B in rat primary hepatocytes Compound was evaluated for inhibition of Mono aminoxidase B in rat primary hepatocytes	[PMID: 12127518]
L02	IC₅₀	213 μg/mL Compound: 1; LZN	Cytotoxicity against human L02 cells after 48 hrs by MTT assay Cytotoxicity against human L02 cells after 48 hrs by MTT assay	10.1039/C5MD00101C
MG-63	IC₅₀	> 400 μg/mL Compound: Linezolid	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MRC5	IC₅₀	> 400 μg/mL Compound: LIN	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38784477]
NIH3T3	IC₅₀	465 μg/mL Compound: Linezolid	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 19819597]
Osteoblast	IC₅₀	> 400 μg/mL Compound: Linezolid	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	> 400 μg/mL Compound: Linezolid	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
THP-1	EC₅₀	0.18 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP-1 cells at pH 5.5 after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP-1 cells at pH 5.5 after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.29 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.35 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 7.4 after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 7.4 after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.47 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.4 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.62 mg/L Compound: Linezolid	Antimicrobial activity against Listeria monocytogenes infected in THP1 cells after 24 hrs Antimicrobial activity against Listeria monocytogenes infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.63 mg/L Compound: Linezolid	Antimicrobial activity against Staphylococcus aureus infected in THP1 cells after 24 hrs Antimicrobial activity against Staphylococcus aureus infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.63 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.63 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.7 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	0.84 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	2.78 mg/L Compound: Linezolid	Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells after 24 hrs Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	2.99 mg/L Compound: Linezolid	Antimicrobial activity against Staphylococcus epidermidis infected in THP1 cells after 24 hrs Antimicrobial activity against Staphylococcus epidermidis infected in THP1 cells after 24 hrs	[PMID: 20385852]
THP-1	EC₅₀	8.45 mg/L Compound: Linezolid	Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs	[PMID: 20385852]
Vero	IC₅₀	> 200 μg/mL Compound: Linezolid	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30145051]
Vero	IC₅₀	> 64 μg/mL Compound: Linezolid	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28523106]
Vero	IC₅₀	> 64 μg/mL Compound: Linezolid	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32666789]
Vero	IC₅₀	> 64 μg/mL Compound: Linezolid	Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by MTT assay	[PMID: 39236219]

In Vitro

Linezolid (PNU-100766) prevents the synthesis of bacterial protein via binding to rRNA on both the 30S and 50S ribosomal subunits^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

337.35

Formula

C₁₆H₂₀FN₃O₄

CAS No.

165800-03-3

Appearance

Solid

Color

White to off-white

SMILES

O=C(O[C@H]1CNC(C)=O)N(C1)C2=CC(F)=C(N3CCOCC3)C=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (296.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9643 mL	14.8214 mL	29.6428 mL
5 mM	0.5929 mL	2.9643 mL	5.9286 mL
10 mM	0.2964 mL	1.4821 mL	2.9643 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (275 KB) SDS (419 KB)

COA (248 KB) HNMR (127 KB) RP-HPLC (246 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828. [Content Brief]

[2]. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88. [Content Brief]

[3]. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51. [Content Brief]

[4]. He MZ, Jiang YW, Cai C. Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2. [Content Brief]

[5]. Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G. Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice. Antimicrob Agents Chemother. 2012 Jul 30. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.9643 mL	14.8214 mL	29.6428 mL	74.1070 mL
	5 mM	0.5929 mL	2.9643 mL	5.9286 mL	14.8214 mL
	10 mM	0.2964 mL	1.4821 mL	2.9643 mL	7.4107 mL
	15 mM	0.1976 mL	0.9881 mL	1.9762 mL	4.9405 mL
	20 mM	0.1482 mL	0.7411 mL	1.4821 mL	3.7054 mL
	25 mM	0.1186 mL	0.5929 mL	1.1857 mL	2.9643 mL
	30 mM	0.0988 mL	0.4940 mL	0.9881 mL	2.4702 mL
	40 mM	0.0741 mL	0.3705 mL	0.7411 mL	1.8527 mL
	50 mM	0.0593 mL	0.2964 mL	0.5929 mL	1.4821 mL
	60 mM	0.0494 mL	0.2470 mL	0.4940 mL	1.2351 mL
	80 mM	0.0371 mL	0.1853 mL	0.3705 mL	0.9263 mL
	100 mM	0.0296 mL	0.1482 mL	0.2964 mL	0.7411 mL

Linezolid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Linezolid165800-03-3PNU-100766PNU100766PNU 100766BacterialAntibioticInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Linezolid (Synonyms: PNU-100766)

Customer Review

Other Forms of Linezolid:

Linezolid Related Antibodies

52 Publications Citing Use of MCE Linezolid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Linezolid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Linezolid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report